Researchers from the University of Texas El Paso (UTEP), funded by Premier Biomedical, Inc., recently developed a single antibody that has the ability to bind three immune inhibitors, CTLA-4, PD1, and BTLA. Last May, a Provisional Patent Application was completed for this antibody family by Premier Biomedical.
Premier Biomedical, Inc. (OTCQB: “BIEI”) is a company focused on discovery and development of medical therapies for several human diseases, such as cancer, sepsis and multiple sclerosis. Premier features several prominent research collaborators, such as the Department of Defense’s Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). Premier Biomedical is preparing an application for approval by the Food and Drug Administration (FDA) for this new antibody to be used as a key cancer immunotherapy drug, an approach designed to potentiate immune responses in order to fight cancer.
Dr. David Vigerust, Vice President of Scientific Development of Premier Biomedical, said in the news release that they are very enthusiastic about this new advancement discovered together with the UTEP team. He added that their first results showed higher adhesion to CTLA-4, a protein receptor that downregulates the immune system and improves blocking, than previous studies have ever demonstrated. This antibody has the potential to perform better than the already available anti-cancer compounds. These promising results accelerated the launch of the test and development program.
William A. Hartman, President and CEO of Premier Biomedical, stated that this new development positions the company as an authority on cancer research in an industry that has been valued at over 40 billion dollars. He added that they will do everything in their means to finish laboratory experiments and move into human clinical studies as quickly as possible in order to accelerate drug development toward FDA approval.
Dr. Georgialina Rodriguez of UTEP, a principal investigator on the project said the research team together with Premier are heavily involved in understanding more about the way these immune therapies or cancer checkpoint inhibitors function to fight and eliminate cancer, including antibodies that target molecules like CTLA4 on T-cells, a protein receptor that downregulates the immune system. Recent findings showed that targeting more than one of these proteins may have superior ability to fight cancer making this research very stimulating.